Antimicrobial prescribing: nebulised liposomal amikacin - evidence summary (ES36)

This concludes nebulised liposomal amikacin may be an option for treating non-tuberculous mycobacterial lung infections caused by Mycobacterium avium complex in combination with other antimicrobial agents in adults with limited treatment options & who do not have cystic fibrosis.

National Institute for Health and Care Excellence